Seneca Biopharma Common Stock

The latest common stock for SNCA is $170K as of December 2020. That compares with $39K in the prior-year period — up 347.3% year over year. Investors often review this figure alongside Seneca Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, SNCA's common stock moved from $39K to $170K — a 347.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Seneca Biopharma's operating scale or balance-sheet position.

A common stock figure of $170K for SNCA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting SNCA's common stock ($170K), review year-over-year change from $39K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Seneca Biopharma's common stock against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.